{"title":"Design, Synthesis, and Evaluation of Halo-Substituted Flavonols Against Melanoma A375 Cells","authors":"Tzu-Yun Sheng, Kuan-Ying Huang, Yu-Jui Su, Sin-Min Li, Tiffany Tze-Jun Luh, Ting-Yu Tsai, Sy-Chyi Cheng, Jih-Jung Chen, Tzenge-Lien Shih","doi":"10.1002/cmdc.70549","DOIUrl":null,"url":null,"abstract":"<p>Malignant melanoma is one of the most aggressive forms of skin cancer. Despite advances in targeted therapy and immunotherapy, the emergence of drug resistance and limited therapeutic efficacy in advanced stages remain major clinical challenges. In this study, a series of novel flavonols were synthesized and evaluated for their cytotoxic activity against human malignant melanoma A375 cells. Among the tested compounds, compound <b>4j</b> exhibited the most potent inhibitory effect, with an IC<sub>50</sub> value of 25.07 ± 2.24 μM, outperforming 5-fluorouracil (5-FU) used as a positive control. Furthermore, Western blot analysis revealed that compound <b>4j</b> modulated the expression of key apoptotic regulators: it downregulated the anti-apoptotic protein Bcl-2, upregulated the pro-apoptotic protein Bax, and activated caspase-3, indicating induction of apoptosis via a caspase-dependent mitochondrial pathway. Molecular docking analysis further showed that the halogenated derivatives exhibited distinct interaction patterns within the Bcl-2 binding groove, supporting the observed positional structure–activity relationship. These findings demonstrate that compound <b>4j</b> possesses promising anticancer activity against malignant melanoma cells. They support flavonols as valuable scaffolds for the development of new anti-melanoma agents, with compound <b>4j</b> emerging as a particularly compelling lead candidate.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 20","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.70549","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Malignant melanoma is one of the most aggressive forms of skin cancer. Despite advances in targeted therapy and immunotherapy, the emergence of drug resistance and limited therapeutic efficacy in advanced stages remain major clinical challenges. In this study, a series of novel flavonols were synthesized and evaluated for their cytotoxic activity against human malignant melanoma A375 cells. Among the tested compounds, compound 4j exhibited the most potent inhibitory effect, with an IC50 value of 25.07 ± 2.24 μM, outperforming 5-fluorouracil (5-FU) used as a positive control. Furthermore, Western blot analysis revealed that compound 4j modulated the expression of key apoptotic regulators: it downregulated the anti-apoptotic protein Bcl-2, upregulated the pro-apoptotic protein Bax, and activated caspase-3, indicating induction of apoptosis via a caspase-dependent mitochondrial pathway. Molecular docking analysis further showed that the halogenated derivatives exhibited distinct interaction patterns within the Bcl-2 binding groove, supporting the observed positional structure–activity relationship. These findings demonstrate that compound 4j possesses promising anticancer activity against malignant melanoma cells. They support flavonols as valuable scaffolds for the development of new anti-melanoma agents, with compound 4j emerging as a particularly compelling lead candidate.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.